Autoantibodies in immune-mediated neuropathies

Current Opinion in Neurology

Volumn 25, Issue 5, 2012, Pages 550-555

  Chavada, Govind ^a   Willison, Hugh J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

antibody; glycolipid; neuropathy; nodal proteins

Indexed keywords

AUTOANTIBODY; CROSS REACTING ANTIBODY; CYTOKINE; GANGLIOSIDE; GANGLIOSIDE GALNAC; GANGLIOSIDE GD 1A; GANGLIOSIDE GM1; GANGLIOSIDE GM1B; GLYCOLIPID; HEMOGLOBIN A1C; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; MYELIN ASSOCIATED GLYCOPROTEIN; NEUROFASCIN; NF186; PARAPROTEIN; PROTEIN NODAL; UNCLASSIFIED DRUG;

ACUTE MOTOR AXONAL NEUROPATHY; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; BRACHIAL PLEXUS NEUROPATHY; CD4 LYMPHOCYTE COUNT; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; DIABETIC NEUROPATHY; DISTAL ACQUIRED DEMYELINATING SYMMETRICAL NEUROPATHY; ELECTROMYOGRAPHY; ELECTROPHYSIOLOGY; ENVENOMATION; EXTENSOR DIGITORUM COMMUNIS MUSCLE; GUILLAIN BARRE SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INFECTION; INFLUENZA VACCINATION; INSULIN DEPENDENT DIABETES MELLITUS; LEPROSY; MOTOR NEUROPATHY; MUSCLE; MYASTHENIA GRAVIS; MYCOPLASMA PNEUMONIA; NERVE INJURY; NEUROPATHY; PARAPROTEINEMIA; REVIEW; SEROLOGY;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; DIABETES MELLITUS, TYPE 1; GANGLIOSIDES; GLYCOLIPIDS; GUILLAIN-BARRE SYNDROME; HUMANS; INFLUENZA VACCINES; LEPROSY; PARAPROTEINS; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84866319049     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328357a77f     Document Type: Review

References (49)

1. Ariga T, Yu RK. Antiglycolipid antibodies in Guillain-Barre syndrome and related diseases: review of clinical features and antibody specificities. J Neurosci Res 2005; 80:1-17. (Pubitemid 40577288)
2. Kusunoki S, Iwamori M, Chiba A, et al. GM1b is a new member of antigen for serum antibody in Guillain-Barre syndrome. Neurology 1996; 47:237-242. (Pubitemid 26243890)
3. Sekiguchi Y, Uncini A, Yuki N, et al. Antiganglioside antibodies are associated with axonal Guillain-Barre syndrome: a Japanese-Italian collaborative study. J Neurol Neurosurg Psychiatry 2012; 83:23-28.
4. Kuijf ML, van Doorn PA, Tio-Gillen AP, et al. Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA. J Neurol Sci 2005; 239:37-44. (Pubitemid 41617413)
5. Ilyas AA, Mithen FA, Dalakas MC, et al. Antibodies to acidic glycolipids in Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 1992; 107:111-121.
6. Inuzuka T, Miyatani N, Baba H, et al. IgM binding to sialosyllactosaminylparagloboside in a patient with polyradiculoneuropathy due to Mycoplasma pneumoniae infection. Acta Neurol Scand 1988; 78:53-57.
7. Fredman P, Vedeler CA, Nyland H, et al. Antibodies in sera from patients with inflammatory demyelinating polyradiculoneuropathy react with ganglioside LM1 and sulphatide of peripheral nerve myelin. J Neurol 1991; 238:75-79.
8. Kuwahara M, Suzuki S, Takada K, Kusunoki S. Antibodies to LM1 and LM1-containing ganglioside complexes in Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 2011; 239:87-90.
9. Nguyen TP, Chaudhry V. Multifocal motor neuropathy. Neurol India 2011; 59:700-706.
10. Cats EA, Jacobs BC, Yuki N, et al. Multifocal motor neuropathy: association of anti-GM1 IgM antibodies with clinical features. Neurology 2010; 75:1961-1967.
11. Allen D, Giannopoulos K, Gray I, et al. Antibodies to peripheral nerve myelin proteins in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2005; 10:174-180. (Pubitemid 40984891)
12. Yan WX, Archelos JJ, Hartung HP, Pollard JD. P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001; 50:286-292. (Pubitemid 32848730)
13. Moriguchi K, Miyamoto K, Takada K, Kusunoki S. Four cases of antiganglioside antibody-positive neuralgic amyotrophy with good response to intravenous immunoglobulin infusion therapy. J Neuroimmunol 2011; 238:107-109.
14. Nishijima T, Tsukada K, Takeuchi S, et al. Antiretroviral therapy for treatmentnaive chronic HIV-1 infection with an axonal variant of Guillain-Barre syndrome positive for antiganglioside antibody: a case report. Intern Med 2011; 50:2427-2429.
15. Christiansen D, Vaughan HA, Milland J, et al. Antibody responses to glycolipid-borne carbohydrates require CD4 + T cells but not CD1 or NKT cells. Immunol Cell Biol 2011; 89:502-510.
16. Neil J, Choumet V, Le Coupanec A, et al. Guillain-Barre syndrome: first description of a snake envenomation aetiology. J Neuroimmunol 2012; 242:72-77.
17. Tracy JA, Dyck PJ. Auto-immune polyradiculoneuropathy and a novel IgG in workers exposed to aerosolized porcine brain. J Peripher Nerv Syst 2011; 16 (Suppl. 1):34-37.
18. Susuki K, Yuki N, Schafer DP, et al. Dysfunction of nodes of Ranvier: a mechanism for antiganglioside antibody-mediated neuropathies. Exp Neurol 2012; 233:534-542.
19. Kuwabara S, Kokubun N, Misawa S, et al. Neuromuscular transmission is not impaired in axonal Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 2011; 82:1174-1177.
20. Fewou SN, Rupp A, Nickolay LE, et al. Antiganglioside antibody internalization attenuates motor nerve terminal injury in a mouse model of acute motor axonal neuropathy. J Clin Invest 2012; 122:1037-1051.
21. Rupp A, Morrison I, Barrie JA, et al. Motor nerve terminal destruction and regeneration following antiganglioside antibody and complement-mediated injury: an in and ex vivo imaging study in the mouse. Exp Neurol 2012; 233:836-848.
22. Zhang G, Lehmann HC, Manoharan S, et al. Anti-ganglioside antibodymediated activation of RhoA induces inhibition of neurite outgrowth. J Neurosci 2011; 31:1664-1675.
23. Zhang G, Lehmann HC, Bogdanova N, et al. Erythropoietin nerve repair in antiganglioside antibody-mediated models of immune neuropathy. PLoS One 2011; 6:e27067.
24. Gu Y, Chen ZW, Siegel A, et al. Analysis of humoral immune responses to LM1 ganglioside in guinea pigs. J Neuroimmunol 2012; 246:58-64.
25. Poduslo JF, Curran GL, Dyck PJ. Increase in albumin, IgG, and IgM blood-nerve barrier indices in human diabetic neuropathy. Proc Natl Acad Sci USA 1988; 85:4879-4883.
26. Poduslo JF, Curran GL. Increased permeability across the blood-nerve barrier of albumin glycated in vitro and in vivo from patients with diabetic polyneuropathy. Proc Natl Acad Sci USA 1992; 89:2218-2222.
27. Lucchetta M, Rudilosso S, Costa S, et al. Antiganglioside autoantibodies in type 1 diabetes. Muscle Nerve 2010; 41:50-53.
28. Sharma MB, Chaudhry R, Tabassum I, et al. The presence of Mycoplasma pneumoniae infection and GM1 ganglioside antibodies in Guillain-Barre syndrome. J Infect Dev Ctries 2011; 5:459-464.
29. Wang DJ, Boltz DA, McElhaney J, et al. No evidence of a link between influenza vaccines and Guillain-Barre syndrome-associated antiganglioside antibodies. Influenza Other Resp Viruses 2012; 6:159-166.
30. Lei T, Siu KL, Kok KH, et al. Antiganglioside antibodies were not detected in human subjects infected with or vaccinated against 2009 pandemic influenza A (H1N1) virus. Vaccine 2012; 30:2605-2610.
31. Kaida K, Morita D, Kanzaki M, et al. Antiganglioside complex antibodies associated with severe disability in GBS. J Neuroimmunol 2007; 182:212-218. (Pubitemid 46026709)
32. Kaida K, Sonoo M, Ogawa G, et al. GM1/GalNAc-GD1a complex: a target for pure motor Guillain-Barre syndrome. Neurology 2008; 71:1683-1690.
33. Nobile-Orazio E, Giannotta C, Briani C. Antiganglioside complex IgM antibodies in multifocal motor neuropathy and chronic immune-mediated neuropathies. J Neuroimmunol 2010; 219:119-122.
34. Greenshields KN, Halstead SK, Zitman FM, et al. The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice. J Clin Invest 2009; 119:595-610.
35. Mauri L, Casellato R, Ciampa MG, et al. Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a. Glycobiology 2012; 22:352-360.
36. Zitman FMP, Greenshields KN, Kuijf ML, et al. Neuropathophysiological potential of Guillain-Barré syndrome antiganglioside-complex antibodies at mouse motor nerve terminals. Clin Exp Neuroimmunol 2011; 2: 59-67.
37. Rinaldi S, Brennan KM, Willison HJ. Combinatorial glycoarray. Methods Mol Biol 2012; 808:413-423.
38. Lonigro A, Devaux JJ. Disruption of neurofascin and gliomedin at nodes of Ranvier precedes demyelination in experimental allergic neuritis. Brain 2009; 132 (Pt 1):260-273.
39. Devaux JJ, Odaka M, Yuki N. Nodal proteins are target antigens in Guillain-Barre syndrome. J Peripher Nerv Syst 2012; 17:62-71.
40. Pruss H, Schwab JM, Derst C, et al. Neurofascin as a target in Guillain-Barre syndrome. Brain 2011; 134 (Pt 5):e173; author reply e174.
41. Latov N. Antibodies to glycoconjugates in neuropathy and motor neuron disease. Prog Brain Res 1994; 101:295-303.
42. Dalakas MC, Rakocevic G, Salajegheh M, et al. Placebo-controlled trial of rituximab in IgM antimyelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 2009; 65:286-293.
43. Maurer MA, Rakocevic G, Leung CS, et al. Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity. J Clin Invest 2012; 122:1393-1402.
44. Ariga T. The role of sulfoglucuronosyl glycosphingolipids in the pathogenesis of monoclonal IgM paraproteinemia and peripheral neuropathy. Proc Jpn Acad Ser B Phys Biol Sci 2011; 87:386-404.
45. Matà S, Borsini W, Ambrosini S, et al. IgM monoclonal gammopathy-associated neuropathies with different IgM specificity. Eur J Neurol 2011; 18:1067-1073.
46. Larue S, Bombelli F, Viala K, et al. Nonanti-MAG DADS neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases. Eur J Neurol 2011; 18:899-905.
47. Remiche G, Kentos A, Mavroudakis N. Distal acquired demyelinating symmetric neuropathy associated with anti-GM1 antibodies: is this a CIDP variant? Acta Neurol Belg 2010; 110:103-106.
48. Singh K, Singh B, Ray P. Anticeramide antibodies in leprosy: marker for nerve damage? J Infect Dev Ctries 2010; 4:378-381.
49. Raju R, Devi SK, Mehervani C, et al. Antibodies to myelin P0 and ceramide perpetuate neuropathy in long standing treated leprosy patients. Neurochem Res 2011; 36:766-773.